Clinical Trial Update: Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating sequential RO-MTX after therapy with pomalidomide, orelabrutinib, and rituximab (POR) in newly diagnosed primary central nervo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Pomalidomide (Pomalidomide)
• RO-MTX
• Rituximab (rituximab)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Primary Central Nervous System Lymphoma | Phase 2 | Status: UNKNOWN